POSTTRANSPLANT ORAL IRON-CHELATING THERAPY IN PATIENTS WITH beta-THALASSEMIA MAJOR

Yesilipek M. A., Karasu G., Kazik M., Uygun V., Ozturk Z.

PEDIATRIC HEMATOLOGY AND ONCOLOGY, vol.27, no.5, pp.374-379, 2010 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 27 Issue: 5
  • Publication Date: 2010
  • Doi Number: 10.3109/08880011003739463
  • Journal Name: PEDIATRIC HEMATOLOGY AND ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.374-379
  • Keywords: bone marrow transplantation, iron overload, thalassemia, BONE-MARROW-TRANSPLANTATION, SERUM FERRITIN, OVERLOAD, DEFERASIROX, BURDEN
  • Akdeniz University Affiliated: Yes

Abstract

Allogeneic hematopoetic stem cell transplantation (HSCT) is the only radical cure of beta-thalassemia. However, iron overload remains a cause of morbidity and mortality in posttransplant period. The authors present 7 patients as a preliminary report who underwent bone marrow transplant (BMT) and received oral chelating therapy (deferasirox) because of poor compliance to phlebotomy and desferrioxamine. The patients investigated mainly for possible side effects of deferasirox. No negative effect was seen in aspartate aminotransferase (AST), alanine aminotransferase (ALT), hemoglobin (Hb), and donor chimerism of the patients while serum ferritin levels significantly reduced (P = .018). Although serum creatinin significantly increased (P = .034), it was in normal limits in all patients. The authors believe that this report shows promising findings to plan further studies to clarify clinical safety and efficacy of deferasirox in posttransplant period.